Zobrazeno 1 - 10
of 315
pro vyhledávání: '"Recurrent ovarian carcinoma"'
Autor:
Thomas J. Herzog, Ignace Vergote, Leonard G. Gomella, Tsveta Milenkova, Tim French, Raffi Tonikian, Christian Poehlein, Maha Hussain
Publikováno v:
European Journal of Cancer. 179:136-146
Poly (ADP-ribose) polymerase inhibitors (PARPis) have demonstrated clinical activity in patients with BRCA1 and/or BRCA2 mutated breast, ovarian, prostate, and pancreatic cancers. Notably, BRCA mutations are associated with defects in the homologous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c9457b38bdb4221e9f9b72bb3da9c89
https://doi.org/10.1016/j.ejca.2022.10.021
https://doi.org/10.1016/j.ejca.2022.10.021
Autor:
Isabelle Ray-Coquard, Ioana Braicu, Regina Berger, Sven Mahner, Jalid Sehouli, Eric Pujade-Lauraine, Philippe Alexandre Cassier, Ute Martha Moll, Hanno Ulmer, Karin Leunen, Alain Gustave Zeimet, Christian Marth, Ignace Vergote, Nicole Concin
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting
Externí odkaz:
https://doaj.org/article/8601cb9f6b384df886c2d55dca630015
Autor:
Carol Aghajanian, Lee-may Chen, Scott H. Kaufmann, Amit M. Oza, Geoffrey I. Shapiro, Rebecca Kristeleit, Sandra Goble, Iain A. McNeish, Diane Provencher, Ana Oaknin, Alexandra Leary, Lara Maloney, Elizabeth M. Swisher, Isabelle Ray-Coquard, Howard A. Burris, Stephen Welch, Kevin K. Lin, Tanya Kwan, Ronnie Shapira-Frommer, Anna V. Tinker, David M. O'Malley, Robert L. Coleman
Publikováno v:
Gynecologic Oncology. 163:490-497
Objective. To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. Methods. This post hoc analysis po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95105e68c62cd8bdd8696a08547ee983
https://doi.org/10.1016/j.ygyno.2021.08.030
https://doi.org/10.1016/j.ygyno.2021.08.030
Autor:
Sezai Vatansever, Naziye Ak
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:1787-1791
What is known and objective Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab. Case summary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a56623313d6cefeab46309113a44631
https://doi.org/10.1111/jcpt.13364
https://doi.org/10.1111/jcpt.13364
Autor:
Carol Aghajanian, Paul DiSilvestro, Robert L. Coleman, Bradley J. Monk, Matthew A. Powell, Michael W. Sill, Stephen C. Rubin, Robert S. Mannel, John H. Farley, Leslie M. Randall, Krishnansu S. Tewari
Publikováno v:
Gynecol Oncol
Objective To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. Methods An explorat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea4eaef932134818781118c892f738d
https://doi.org/10.1016/j.ygyno.2020.07.015
https://doi.org/10.1016/j.ygyno.2020.07.015
Autor:
Alicia Hernández, J. Feliu, J Brenes, Alberto Berjón, Andrés Redondo, Jorge L Ramón-Patino, Eugenia Espinosa, G Casado, Marta Mendiola, Beatriz Castelo, David Hardisson, A Gallego
Publikováno v:
Clinical and Translational Oncology. 23:536-542
Treatment of recurrent ovarian carcinoma is a challenge, particularly for the clear cell (CCC) subtype. However, there is a preclinical rationale that these patients could achieve a benefit from antiangiogenic therapy. To assess this hypothesis, we u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e7db899d32995156b1f539b5a1ea49c
https://doi.org/10.1007/s12094-020-02446-z
https://doi.org/10.1007/s12094-020-02446-z
Autor:
Bradley J. Monk, Jiaru Bai, Kathleen N. Moore, Krishnansu S. Tewari, Rebecca Kristeleit, Juliet E Wolford
Publikováno v:
Gynecol Oncol
Background Olaparib was approved on December 19, 2014 by the US FDA as 4th-line therapy (and beyond) for patients with germline BRCA1/2 mutations; rucaparib was approved on December 19, 2016 as 3rd-line therapy (and beyond) for germline or somatic BR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f7445d34acdb8341bb130e8f230fe58
https://doi.org/10.1016/j.ygyno.2020.02.030
https://doi.org/10.1016/j.ygyno.2020.02.030
Autor:
Guseinov Kd, T.V. Gorodnova, Kireeva Gs, A.M. Belyaev, A.F. Urmancheeva, M.G. Yakovleva, I.V. Berlev, M.G. Shikhzadaeva
Publikováno v:
Doctor.Ru. 19:62-68
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4982100a3022fd4348b1e8ace6563146
https://doi.org/10.31550/1727-2378-2020-19-1-62-68
https://doi.org/10.31550/1727-2378-2020-19-1-62-68
Autor:
Sadananda Rao Manjunath, Ganapathi Ramanan, Vidyasagar Devaprasad Dedeepiya, Hiroshi Terunuma, Xuewen Deng, Subramani Baskar, Rajappa Senthilkumar, Paramasivam Thamaraikannan, Thangavelu Srinivasan, Senthilkumar Preethy, Samuel J.K. Abraham
Publikováno v:
Case Reports in Oncology, Vol 5, Iss 1, Pp 114-118 (2012)
Current therapeutic modalities for ovarian cancer such as chemotherapy, radiotherapy and surgery have been reported to yield only marginal success in improving survival rates of patients and have associated adverse effects. We report here a case of r
Externí odkaz:
https://doaj.org/article/b129ecc1b955441482c3df44e297c4bd
Autor:
Sylvia Stadlmann, Salvatore Piscuoglio, Alexander Wilhelm, Ornella Neri, Alexandros Lalos, Raoul A. Droeser, Caner Ercan, Gad Singer, Benjamin Weixler, Alberto Posabella, Sebastian Staubli, Luigi Terracciano, Giulio C. Spagnoli
Publikováno v:
Cancers, Vol 13, Iss 5783, p 5783 (2021)
Cancers
Volume 13
Issue 22
Cancers
Volume 13
Issue 22
Background: Ovarian cancer (OC) is the most aggressive and fatal malignancy of the female reproductive system. Debulking surgery with adjuvant chemotherapy represents the standard treatment, but recurrence rates are particularly high. Over the past d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebf2b0ba6dd982d5efc64d3a5bc9b53d
https://www.mdpi.com/2072-6694/13/22/5783
https://www.mdpi.com/2072-6694/13/22/5783